Advisory Research’s Antares Pharma, Inc. ATRS Stock Holding History

Advisory Research’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-122,622	Closed	-$576K	–	359
2019 Q4	$576K	Buy	+122,622	New	+$502K	0.03%	232

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Advisory Research's ATRS Position: Q1 2020 in Review

Advisory Research sold out of Antares Pharma, Inc. (ATRS) in Q1 2020, closing a stake of 122,622 shares — an estimated $576K sold.

Advisory Research first reported a position in ATRS in Q4 2019 and held it in 1 quarter. The position peaked at $576K in Q4 2019. 154 funds tracked by Wall St. Rank hold ATRS as of Q1 2020.

Advisory Research reported no remaining Antares Pharma, Inc. position as of Q1 2020 after selling out during the quarter.
Advisory Research sold 122,622 Antares Pharma, Inc. shares in Q1 2020, an estimated $576K.
Advisory Research first reported a position in Antares Pharma, Inc. in Q4 2019 and held it in 1 quarter.
Advisory Research's Antares Pharma, Inc. position peaked at $576K in Q4 2019.
154 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2020.

Based on Advisory Research's 13F filing for Q1 2020, filed 12 May 2020.